Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Edwards Lifesciences Corp (EW)

Edwards Lifesciences Corp (EW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

What to Expect From Edwards Lifesciences' Next Quarterly Earnings Report

Edwards Lifesciences Corporation (EW), headquartered in Irvine, California, provides products and technologies for structural heart disease and critical care monitoring. Valued at $48 billion by market cap, the company offers products such as tissue replacement heart valves, heart valve repair, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals. The leading global structural heart innovation company is expected to announce its fiscal first-quarter earnings for 2026 in the near term.

Ahead of the event, analysts expect EW to report a profit of $0.72 per share on a diluted basis, up 12.5% from $0.64 per share in the year-ago quarter. The company beat the...

Fundamentals

See More
  • Market Capitalization, $K 46,080,672
  • Shares Outstanding, K 580,800
  • Annual Sales, $ 6,068 M
  • Annual Income, $ 1,074 M
  • EBIT $ 1,264 M
  • EBITDA $ 1,421 M
  • 60-Month Beta 0.93
  • Price/Sales 7.86
  • Price/Cash Flow 28.79
  • Price/Book 4.61

Options Overview Details

View History
  • Implied Volatility 37.67% (-1.67%)
  • Historical Volatility 28.63%
  • IV Percentile 87%
  • IV Rank 57.43%
  • IV High 52.16% on 04/08/25
  • IV Low 18.11% on 08/28/25
  • Expected Move (DTE 17) 4.08 (5.13%)
  • Put/Call Vol Ratio 0.26
  • Today's Volume 623
  • Volume Avg (30-Day) 1,172
  • Put/Call OI Ratio 1.41
  • Today's Open Interest 47,081
  • Open Int (30-Day) 58,773
  • Expected Range 75.42 to 83.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.72
  • Number of Estimates 10
  • High Estimate 0.73
  • Low Estimate 0.71
  • Prior Year 0.64
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
78.39 +1.42%
on 03/30/26
87.32 -8.96%
on 03/02/26
-6.97 (-8.06%)
since 02/27/26
3-Month
74.66 +6.48%
on 02/11/26
87.44 -9.08%
on 12/29/25
-7.35 (-8.46%)
since 12/26/25
52-Week
65.94 +20.56%
on 04/09/25
87.89 -9.55%
on 12/05/25
+8.59 (+12.11%)
since 03/28/25

Most Recent Stories

More News
Two Year Data on Edwards Lifesciences’ EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits

TRISCEND II randomized trial data presented at ACC show lower mortality with EVOQUE system, when accounting for patient crossover

EW : 79.50 (+0.20%)
What to Expect From Edwards Lifesciences' Next Quarterly Earnings Report

Edwards Lifesciences will release its first-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth.

EW : 79.50 (+0.20%)
XLV : 143.82 (+0.39%)
$SPX : 6,343.72 (unch)
Is Edwards Lifesciences Stock Outperforming the S&P 500?

Edwards Lifesciences has outperformed the S&P 500 recently, and analysts remain moderately optimistic about the stock’s prospects.

EW : 79.50 (+0.20%)
$SPX : 6,343.72 (unch)
MDT : 85.74 (-1.61%)
Edwards Lifesciences Advances Structural Heart Care Through Innovation and Purpose

At the close of Heart Month, Edwards Lifesciences (NYSE: EW) underscored its leadership in structural heart innovation, advancing care through deep expertise and strong partnerships so people with structural...

EW : 79.50 (+0.20%)
Edwards Lifesciences to Present at the Barclays and Leerink Partners Global Healthcare Conferences

Edwards Lifesciences Corporation (NYSE: EW) today announced its chief financial officer, Scott Ullem, is scheduled to present at two upcoming conferences: Tuesday, March 10, 2026...

EW : 79.50 (+0.20%)
Edwards Lifesciences to Present at Citi’s 2026 Unplugged Medtech and Life Sciences Access Day

Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in Citi’s Unplugged Medtech and Life Sciences Access Day on February 26, 2026. Scott Ullem, chief financial...

EW : 79.50 (+0.20%)
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH

With after-tax profits surging by close to 50% year-over-year, AstraZeneca emerges as a potential winner among healthcare names reporting earnings this month.

ZBH : 88.62 (+0.06%)
EW : 79.50 (+0.20%)
AZN : 193.88 (+2.90%)
Edwards Lifesciences Reports Fourth Quarter Results

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025. Highlights and Outlook ...

EW : 79.50 (+0.20%)
What Are Wall Street Analysts' Target Price for Edwards Lifesciences Stock?

While Edwards Lifesciences has underperformed the S&P 500 over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

EW : 79.50 (+0.20%)
$SPX : 6,343.72 (unch)
UBS : 36.67 (+0.71%)
IHI : 52.60 (-1.09%)
Edwards Lifesciences to Host Earnings Conference Call on February 10, 2026

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2025 after the market closes on Tuesday, February 10, and will host a conference call at 5:00...

EW : 79.50 (+0.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair...

See More

Key Turning Points

3rd Resistance Point 82.87
2nd Resistance Point 81.75
1st Resistance Point 80.63
Last Price 79.50
1st Support Level 78.38
2nd Support Level 77.26
3rd Support Level 76.14

See More

52-Week High 87.89
Fibonacci 61.8% 79.51
Last Price 79.50
Fibonacci 50% 76.92
Fibonacci 38.2% 74.32
52-Week Low 65.94

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.